Relationship between Glutathione S-Transferase P1 (GSTP1), X-Ray Repair Cross Complementing Group 1 (XRCC1) and 5,10-Methylenetetrahydrofolate Reductase (5,10-MTHFR) Gene Polymorphisms and Response to Chemotherapy in Advanced Gastric Cancer
Relationship between Glutathione S-Transferase P1 (GSTP1), X-Ray Repair Cross Complementing Group 1 (XRCC1) and 5,10-Methylenetetrahydrofolate Reductase (5,10-MTHFR) Gene Polymorphisms and Response to Chemotherapy in Advanced Gastric Cancer
复制标题
谷胱甘肽 S-转移酶 P1 (GSTP1)、X 射线修复交叉互补组 1 (XRCC1) 和 5,10-亚甲基四氢叶酸还原酶 (5,10-MTHFR) 基因多态性与晚期胃癌化疗反应的关系
DOI：
10.1159/000351260
复制
发表时间：
2013-06-01
期刊：
影响因子：
0.3
通讯作者：
Wu, Chang-Ping
中科院分区：
文献类型：
--
作者：
Ji, Mei;Xu, Bin;Wu, Chang-Ping
背景：本研究旨在探讨谷胱甘肽S-转移酶P1（GSTP1）、5,10-亚甲基四氢叶酸还原酶（5,10-MTHFR）和X射线修复交叉互补组1（XRCC1）基因多态性与晚期胃癌化疗反应的关系。患者和方法：纳入59例晚期胃癌患者。所有患者均接受包含多西紫杉醇、顺铂和 5-氟尿嘧啶的 DCF 方案治疗。通过聚合酶链反应/连接酶检测反应（PCR-LDR）分析所有患者的 GSTP1、XRCC1 和 5,10-MTHFR 基因型。结果：GSTP1 中 G/G 基因型 15 例（25.42%），G/A 基因型 21 例（35.59%），A/A 基因型 23 例（38.98%），A/A 基因型 16 例（27.12%），G/A 基因型 18 例（30.51%），25 例。 XRCC1 为 G/G 基因型（42.37%），5,10-MTHFR 为 C/C 基因型 21 例（35.59%），C/T 基因型 22 例（37.29%），T/T 基因型 16 例（27.12%）。化疗2个周期后，完全缓解4例，部分缓解14例，病情稳定19例，疾病进展22例，总有效率30.51%。 GSTP1 G/G 基因型、XRCC1 A/A 基因型和 5,10-MTHFR T/T 基因型的存活率更高 (p < 0.05)。结论：GSTP1 G/G、XRCC1 A/A、5,10-MTHFR T/T基因多态性对预测晚期胃癌DCF方案疗效具有临床价值。
Background: Our study aimed to investigate the relationship between glutathione S-transferase P1 (GSTP1), 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) and X-ray repair cross complementing group 1 (XRCC1) gene polymorphisms and the response to chemotherapy in advanced gastric cancer. Patients and Methods: 59 cases of advanced gastric cancer were enrolled. All patients were treated with the DCF regimen comprising docetaxel, cisplatin, and 5-fluorouracil. All patients' genotypes regarding GSTP1, XRCC1, and 5,10-MTHFR were analyzed by polymerase chain reaction/ligase detection reaction (PCR-LDR). Results: There were 15 (25.42%) cases of G/G genotype, 21 (35.59%) of G/A genotype, and 23 (38.98%) of A/A genotype for GSTP1, 16 (27.12%) cases of A/A genotype, 18 (30.51%) of G/A genotype, and 25 (42.37%) of G/G genotype for XRCC1, and 21 (35.59%) cases of C/C genotype, 22 (37.29%) of C/T genotype, and 16 (27.12%) of T/T genotype for 5,10-MTHFR. After 2 cycles of chemotherapy, there were 4 cases of complete remission, 14 of partial remission, 19 of stable disease, and 22 of advanced disease, with a total effective rate of 30.51%. Better survival was shown for GSTP1 G/G genotype, XRCC1 A/A genotype, and 5,10-MTHFR T/T genotype (p < 0.05). Conclusion: The gene polymorphisms of GSTP1 G/G, XRCC1 A/A, and 5,10-MTHFR T/T have clinical value for predicting the response to the DCF regimen for advanced gastric cancer.